Drug intelligence / Profile preview

MBRC-201

Development stage: Phase 2
Lead developer: MBrace Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MBRC-201 is an investigational antibody-drug conjugate (ADC) currently in early-phase clinical trials for advanced, refractory solid tumors, including specific subtypes such as metastatic castration-resistant prostate cancer, non-small cell lung cancer, breast cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The precise target and payload have not been publicly disclosed. The study aims to assess safety, pharmacokinetics, dose selection, and preliminary antitumor activity in several tumor types. MBRC-201 is being evaluated in multicenter, open-label phase 1/2 trials in heavily pretreated patients with solid tumors[2][3].

Other names: MBRC-201-001MBRC201-001MBRC 201-001

Beyond the preview

Go deeper on MBRC-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBRC-201.

Explore the full profile